Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DTIL Precision BioSciences	$4.77 +1.7%	$4.69	$3.61 ▼ $11.09	$55.28M	1.52	190,797 shs	61,454 shs
PDSB PDS Biotechnology	$1.20 +3.4%	$1.33	$0.85 ▼ $4.29	$53.02M	0.95	445,630 shs	304,321 shs
PRPH ProPhase Labs	$0.33 +1.6%	$0.37	$0.22 ▼ $3.00	$13.60M	-0.48	15.31 million shs	3.38 million shs
UNCY Unicycive Therapeutics	$4.63 +5.0%	$5.28	$2.75 ▼ $11.00	$55.75M	1.88	373,239 shs	530,441 shs

Analysts Agree—These Gold Picks Outshine the Rest

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DTIL Precision BioSciences	+1.71%	+4.38%	+7.19%	+1.27%	-46.76%
PDSB PDS Biotechnology	+3.45%	+7.14%	+2.56%	-15.49%	-60.26%
PRPH ProPhase Labs	+1.56%	+1.96%	-20.07%	-14.08%	-86.70%
UNCY Unicycive Therapeutics	+4.99%	+14.04%	+0.22%	-22.30%	+46.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DTIL Precision BioSciences	4.0592 of 5 stars	3.5	1.0	4.6	2.9	1.7	0.6
PDSB PDS Biotechnology	2.035 of 5 stars	3.7	3.0	0.0	2.5	0.0	0.0
PRPH ProPhase Labs	1.1025 of 5 stars	0.0	5.0	0.0	2.6	0.0	0.6
UNCY Unicycive Therapeutics	2.6381 of 5 stars	3.7	2.0	0.0	2.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DTIL Precision BioSciences	3.00	Buy	$47.00	885.32% Upside
PDSB PDS Biotechnology	3.33	Buy	$9.00	650.00% Upside
PRPH ProPhase Labs	0.00	N/A	N/A	N/A
UNCY Unicycive Therapeutics	3.33	Buy	$60.00	1,195.90% Upside

Current Analyst Ratings Breakdown

Latest PRPH, UNCY, DTIL, and PDSB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/1/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/11/2025	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
5/27/2025	UNCY Unicycive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$90.00
5/21/2025	DTIL Precision BioSciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DTIL Precision BioSciences	$68.70M	0.82	N/A	N/A	$2.89 per share	1.65
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	$0.51 per share	N/A
PRPH ProPhase Labs	$6.77M	2.04	N/A	N/A	$0.25 per share	1.33
UNCY Unicycive Therapeutics	$680K	86.06	N/A	N/A	$0.72 per share	6.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DTIL Precision BioSciences	$7.17M	-$8.81	N/A	N/A	N/A	-6,205.79%	-176.47%	-69.05%	11/3/2025 (Estimated)
PDSB PDS Biotechnology	-$37.61M	-$0.94	N/A	N/A	N/A	N/A	-173.28%	-75.81%	N/A
PRPH ProPhase Labs	-$53.36M	-$1.26	N/A	N/A	N/A	N/A	-230.54%	-68.11%	N/A
UNCY Unicycive Therapeutics	-$36.73M	-$5.10	N/A	N/A	N/A	N/A	-277.30%	-61.53%	N/A

Latest PRPH, UNCY, DTIL, and PDSB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	UNCY Unicycive Therapeutics	-$0.70	-$0.52	+$0.18	-$0.52	N/A	N/A
8/13/2025	Q2 2025	PDSB PDS Biotechnology	-$0.24	-$0.21	+$0.03	-$0.21	N/A	N/A
8/13/2025	Q2 2025	PRPH ProPhase Labs	-$0.15	-$0.11	+$0.04	-$0.11	$3.55 million	$1.25 million
8/7/2025	Q2 2025	DTIL Precision BioSciences	-$0.09	-$2.13	-$2.04	-$2.13	$6.27 million	$0.02 million
5/20/2025	Q1 2025	PRPH ProPhase Labs	-$0.18	-$0.12	+$0.06	$0.12	$2.45 million	$1.43 million
5/15/2025	Q1 2025	DTIL Precision BioSciences	-$0.43	-$2.21	-$1.78	-$2.21	$5.00 million	$0.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DTIL Precision BioSciences	N/A	N/A	N/A	N/A	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	N/A
PRPH ProPhase Labs	N/A	N/A	N/A	N/A	N/A
UNCY Unicycive Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DTIL Precision BioSciences	0.66	5.18	5.18
PDSB PDS Biotechnology	0.29	2.33	2.33
PRPH ProPhase Labs	0.30	1.03	0.98
UNCY Unicycive Therapeutics	N/A	1.64	1.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DTIL Precision BioSciences	37.99%
PDSB PDS Biotechnology	26.84%
PRPH ProPhase Labs	9.45%
UNCY Unicycive Therapeutics	40.42%

Insider Ownership

Company	Insider Ownership
DTIL Precision BioSciences	4.50%
PDSB PDS Biotechnology	9.20%
PRPH ProPhase Labs	9.60%
UNCY Unicycive Therapeutics	10.71%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DTIL Precision BioSciences	200	11.79 million	11.26 million	No Data
PDSB PDS Biotechnology	20	45.71 million	41.51 million	Optionable
PRPH ProPhase Labs	130	41.54 million	37.55 million	Optionable
UNCY Unicycive Therapeutics	9	12.64 million	11.29 million	Not Optionable

PRPH, UNCY, DTIL, and PDSB Headlines

Recent News About These Companies

Unicycive Therapeutics reports Q2 EPS (52c), consensus (70c)

3 hours ago | msn.com

Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

August 14 at 4:14 PM | gurufocus.com

Unicycive Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

August 14 at 3:55 PM | globenewswire.com

Unicycive Therapeutics requests Type A meeting with FDA to discuss CRL

August 14 at 2:05 PM | msn.com

Unicycive Therapeutics expects cash to fund operations into 2H of 2026

August 14 at 2:05 PM | msn.com

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

August 14 at 7:00 AM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 13 at 12:33 PM | globenewswire.com

Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Wednesday

August 12 at 8:43 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 11, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 9, 2025 | globenewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Holdings Lifted by Vivo Capital LLC

August 9, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

August 6, 2025 | prnewswire.com

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Up 1,211.2% in July

August 3, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 31, 2025 | prnewswire.com

Unicycive Therapeutics Inc Ordinary Shares UNCY - Morningstar

July 30, 2025 | morningstar.comM

Unicycive Therapeutics (NASDAQ:UNCY) Trading Down 6.2% - Here's What Happened

July 30, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 28, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 27, 2025 | prnewswire.com

Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology

July 24, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 23, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Unicycive Therapeutics, Inc. - UNCY

July 22, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRPH, UNCY, DTIL, and PDSB Company Descriptions

Precision BioSciences NASDAQ:DTIL

$4.77 +0.08 (+1.71%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$4.74 -0.03 (-0.63%)

As of 08/14/2025 04:38 PM Eastern

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

PDS Biotechnology NASDAQ:PDSB

$1.20 +0.04 (+3.45%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$1.18 -0.01 (-1.25%)

As of 08/14/2025 06:57 PM Eastern

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

ProPhase Labs NASDAQ:PRPH

$0.33 +0.01 (+1.56%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$0.32 -0.02 (-4.96%)

As of 08/14/2025 07:59 PM Eastern

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Unicycive Therapeutics NASDAQ:UNCY

$4.63 +0.22 (+4.99%)

Closing price 08/14/2025 04:00 PM Eastern

Extended Trading

$4.58 -0.04 (-0.97%)

As of 08/14/2025 07:50 PM Eastern

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time